Important pharmacy news and late-breaking industry information updated daily.
In December 2020, the National Asthma Education and Prevention Program (NAEPP) Coordinating Committee released a focused update to its 2007 asthma guidelines. The update covers select topics, such as intermittent use of inhaled corticosteroids (ICS), the role of long-acting muscarinic antagonists (LAMAs), indoor allergy mitigation, use of immunotherapy, bronchial thermoplasty, and fractional exhaled nitric oxide (FeNO) testing.
Many Americans have expressed a preference for Johnson & Johnson's coronavirus vaccine, even though its 72% efficacy rate lags that of the Pfizer and Moderna vaccines, which are about 95% effective. For recipients, the convenience of a single-dose is worth forfeiting the extra cushion of protection.
Texas and Mississippi are getting pushback from major retailers as the governors move ahead with plans to reopen businesses at 100% capacity and drop mask mandates.
President Biden announced Tuesday there will be ample COVID-19 vaccine for "every adult in America" to be protected by the end of May. That milestone previously was set for late July, but the pace has accelerated due to Johnson & Johnson's single-dose vaccine receiving emergency use authorization.
As they help to vaccinate the nation against COVID-19, pharmacies are compiling loads of consumer information on people who schedule appointments.
A December 2020 opinion issued by Washington Attorney General (AG) Bob Ferguson affirmed pharmacists’ standard of practice under collaborative drug therapy agreements (CDTAs).
FDA granted emergency use authorization (EUA) to Janssen’s single-dose COVID-19 vaccine on Saturday, February 27, for adults ages 18 years and older.
Johnson & Johnson received FDA emergency use authorization late Saturday for its coronavirus vaccine, which is recommended in a single dose for adults aged 18 years and older. Not only is the need for a booster injection eliminated, but the new vaccine also will not have to remain frozen until use.
New analyses by FDA and Johnson & Johnson demonstrate that the company's single-dose vaccine has overall efficacy of 72% against COVID-19 in the United States and 86% efficacy against severe cases of the disease. Efficacy was slightly lower in South Africa, which is in the grips of a mutated strain of the virus.
FDA said Monday that it will expedite efforts to gauge the efficacy of coronavirus vaccines against emerging strains.